Journal: Nature Communications

Article Title: Cellular census of human fibrosis defines functionally distinct stromal cell types and states

doi: 10.1038/s41467-020-16264-y

Figure Lengend Snippet: a Force directed graph (Fruchterman–Reingold layout) of single-cell RNA-seq showing myofibroblasts coloured by major subsets ( n = 12 DD patients). MFB represents myofibroblast. b Heatmap of single cell RNA-seq showing the z -score expression of top ten myofibroblast subset markers. Two-sided Wilcoxon Rank Sum Test with FDR correction (BH correction ( n = 12 DD patients). c tSNE projections of single cell RNA-seq showing myofibroblasts coloured by the expression of ACTA2 and MKI67 in scaled log(UMI + 1) ( n = 12 DD patients). d Violin plots showing gene expression of MKI67 and ITGB1 in fibroblasts and myofibroblasts in scaled(log(UMI + 1)) from single cell RNA-seq. e Box and whisker plot of flow cytometry analysis showing Ki67 protein expression in myofibroblasts ITGβ1 high myofibroblasts (range 21–46%, mean 28% and box bounds 24–27% representing first to third quantiles) and ITGβ1 low fibroblasts (range 0–0%, mean 0.0% and percentiles 0%). Two-sided unpaired t test, p value = 0.00014, mean ± SEM. ( n = 8 DD patients). f Dot plot of single cell RNA-seq showing pathways enriched in myofibroblast subsets. Gene ratio is number of marker genes associated with pathway and p .adjust is adjusted p value (two-sided Wilicoxon Rank Sum test, BH FDR-correction). g tSNE projections of CyTOF analysis for representative DD patient showing distinct CD82 high OX40L + myofibroblast. Scale bar is normalised protein expression. ( n = 6 DD patients). h Confocal images of immunofluorescence showing co-expression of CD82, α-SMA and ITG-β1 in DD nodules ( n = 3 DD patients). Scale bar 20 µm.

Article Snippet: CD252 169-Tm (3166007B, ML5, Fluidigm), CD34 166-Er (Catalog:3166012B, Clone:581, Fluidigm), CD45 141-Pr (Catalog: 3141009B, Clone: HI30, Fluidigm), HLAD A, B C 142-Nd (Catalog: 3142007B, Clone: HCD57, Fluidigm), CD19 143-Nd (Catalog: 3144007 A, Clone:NP6G4, Fluidigm), HLA-DR 89-Y (Catalog: 3173005B, L243, Fluidigm), CD3 189-Y (Catalog: 3158021 A, Clone: 24E10, Fluidigm), B-catenin 176-Lu (Catalog: 3147005 A, Clone:D10A8, Fluidigm), CD55 174-Yb (Catalogue; 3148015B, Clone: JS11, Fluidigm), CD146 155-Nd (3155006B, P1H12, Fluidigm), CD29 156-Gd (3156007B, TS2/16, Fluidigm), CD82 158Gd (3158025B, ASL-24, Fluidigm), CD90 172-Yb (3173011B, 5E10, Fluidigm), TGFb 150-Nd (3163010B, CloneTW46H10, Fluidigm) CD163 145-Nd (3145010B, GHI/61, Fluidigm), Ki-67 168-Er (3168007B, B56, Fluidigm), CD54 170-Er (3170014B, HA58, Fluidigm), CD68 171-Yb (3171011B, Y1/82A, Fluidigm), CD9 172-Yb (Cat. No. 312102, Biolegend), CD252 150-Nd (326302, Biolegend), PGLA2 172-Yb (MAB5374, R&D Systems), a-SMA 156-Gr (MAB1420, 1A4, R&D Systems), gp38 155-Gd (AF3670-SP, R&D Systems), PDGFRB 154-Sm (SAB4700458, 18A2, Sigma Aldrich), MMP14 149-Sm (MAB9181-SP, 128527 R&D Systems), Cad-11 148-Nd (AF1790-SP, R&D Systems) and FAP 147-Sm (MAB3715-SP, 427819 RD Systems).

Techniques: RNA Sequencing, Expressing, Gene Expression, Whisker Assay, Flow Cytometry, Marker, Immunofluorescence

Journal: Nature Communications

Article Title: Cellular census of human fibrosis defines functionally distinct stromal cell types and states

doi: 10.1038/s41467-020-16264-y

Figure Lengend Snippet: a Line plot demonstrating CD82 expression in myofibroblasts ( loess smoothed normalised counts ± SE) along pseudotime (myofibroblast activation trajectory) in single-cell RNA-seq ( n = 12 DD patients). b Above, Heatmaps of traction force microscopy analysis showing magnitude of traction force (Pascals) in freshly isolated FACS sorted myofibroblasts (CD82 high and CD82 low ). Below, surface plots of traction force microscopy showing representative force foci from sorted myofibroblasts (Scaled to 800 Pa). Colour scale represents force range per cell. c Bar plots of traction force microscopy analysis showing mean and maximum traction force per cell in CD82 high and CD82 low sorted myofibroblast populations ( n = 3 DD patients, >15 cells per condition). Two-sided unpaired t test, mean ± SEM. p Values = 0.0056 (max traction), and 0.0098 (mean traction). d tSNE projection of traction force microscopy analysis showing clustering of single cell force signatures in sorted populations (CD82 high and CD82 low ) ( n = 3 DD patients, >15 cells per condition). e Box and whisker plot of flow cytometry analysis showing cell cycle phases in siControl and siCD82 transfected DD myofibroblasts ( n = 3 DD patients). Two-sided paired t test, p value = 0.023, mean ± SEM). (siRNA range 2.6–85.5%, mean 32.8% and box bounds 9.75–45.2% represent first and third quantiles. siCD82 range 1.1–87.1%, mean 32.7% and box bounds 3.1–59.8% represent first and third quantiles.) f tSNE projections of single-cell RNA-seq showing fibroblasts and myofibroblasts in bleomycin murine model marked by the expression of selected genes in scaled log(UMI + 1) ( n = 2 mice). g tSNE projection of single cell RNA-seq showing murine fibroblasts and myofibroblasts in bleomycin model coloured by Louvain clusters ( n = 2 mice). h Bar plot of single cell RNA-seq showing the percentage of stromal cells before (Day 0) and after (Day 21) the installation of bleomycin in murine lung fibrosis model. i Confocal images of immunofluorescence showing co-expression of CD82, α-SMA and PDGFR-α in human IPF ( n = 3 independent IPF patients). Scale bar = 20 µm.

Article Snippet: CD252 169-Tm (3166007B, ML5, Fluidigm), CD34 166-Er (Catalog:3166012B, Clone:581, Fluidigm), CD45 141-Pr (Catalog: 3141009B, Clone: HI30, Fluidigm), HLAD A, B C 142-Nd (Catalog: 3142007B, Clone: HCD57, Fluidigm), CD19 143-Nd (Catalog: 3144007 A, Clone:NP6G4, Fluidigm), HLA-DR 89-Y (Catalog: 3173005B, L243, Fluidigm), CD3 189-Y (Catalog: 3158021 A, Clone: 24E10, Fluidigm), B-catenin 176-Lu (Catalog: 3147005 A, Clone:D10A8, Fluidigm), CD55 174-Yb (Catalogue; 3148015B, Clone: JS11, Fluidigm), CD146 155-Nd (3155006B, P1H12, Fluidigm), CD29 156-Gd (3156007B, TS2/16, Fluidigm), CD82 158Gd (3158025B, ASL-24, Fluidigm), CD90 172-Yb (3173011B, 5E10, Fluidigm), TGFb 150-Nd (3163010B, CloneTW46H10, Fluidigm) CD163 145-Nd (3145010B, GHI/61, Fluidigm), Ki-67 168-Er (3168007B, B56, Fluidigm), CD54 170-Er (3170014B, HA58, Fluidigm), CD68 171-Yb (3171011B, Y1/82A, Fluidigm), CD9 172-Yb (Cat. No. 312102, Biolegend), CD252 150-Nd (326302, Biolegend), PGLA2 172-Yb (MAB5374, R&D Systems), a-SMA 156-Gr (MAB1420, 1A4, R&D Systems), gp38 155-Gd (AF3670-SP, R&D Systems), PDGFRB 154-Sm (SAB4700458, 18A2, Sigma Aldrich), MMP14 149-Sm (MAB9181-SP, 128527 R&D Systems), Cad-11 148-Nd (AF1790-SP, R&D Systems) and FAP 147-Sm (MAB3715-SP, 427819 RD Systems).

Techniques: Expressing, Activation Assay, RNA Sequencing, Microscopy, Isolation, Whisker Assay, Flow Cytometry, Transfection, Immunofluorescence

Journal: Cells

Article Title: Long-Term Engraftment and Satellite Cell Expansion from Human PSC Teratoma-Derived Myogenic Progenitors

doi: 10.3390/cells14151150

Figure Lengend Snippet: Scheme outlining the key steps of the study. hiPSCs were injected into TA muscles of NSG mice, and teratomas were harvested two months later. Tissue was digested, and skeletal myogenic progenitor cells co-expressing CD82, ERBB3, and NGFR were sorted by FACS, cultured in vitro, tested for differentiation into myotubes, and, in parallel, transplanted into tibialis anterior (TA) muscles of injured NSG-mdx 4Cv mice following X-ray and cardiotoxin injection. TA muscle tissue was harvested at various time points, and stained sections were analyzed with different antibodies to assess human cell contribution, muscle regeneration, and fiber type differentiation.

Article Snippet: The dissociated cells were incubated with antibodies APC anti-CD82 (FAB4616A, R&D Systems, Minneapolis, MN, USA; RRID: AB_2076404), PE anti-ERBB3 (304706, BioLegend, San Diego, CA, USA; RRID: AB_2099569), and PECy7 anti-NGFR (Cat# 562122, BD Biosciences, San Jose, CA, USA; RRID: AB_10894762); each at 0.5 uL per 1 million cells) in FACS buffer for one hour on ice.

Techniques: Injection, Muscles, Expressing, Cell Culture, In Vitro, Staining

Journal: Cells

Article Title: Long-Term Engraftment and Satellite Cell Expansion from Human PSC Teratoma-Derived Myogenic Progenitors

doi: 10.3390/cells14151150

Figure Lengend Snippet: ( A ) Morphology of teratomas formed in TA muscles of NSG mice two months after injection of hiPSCs. ( B ) Isolation of skeletal myogenic progenitor cells co-expressing CD82, ERBB3, and NGFR by FACS from TA teratomas. ( C ) Expression levels of various myogenic and fibroblastic markers under different growth factor conditions, as determined by RNA sequencing, presenting mean ratio normalized counts. ( D ) Morphology of isolated skeletal myogenic cells cultured at different passages. PAX7 staining of cells in the proliferative phase at confluency, from the same passage used for transplantation. ( E ) MyoD, Myogenin, MF-20, and PAX7 staining of teratoma-derived skeletal myogenic cells in differentiation medium at passage 3, highlighting their capacity to form myotubes. ( F ) Percentage of cells positive for PAX7 in proliferative and differentiation media, and for MyoD, Myogenin, and MF-20 in differentiation medium. Data were obtained from five fields per sample across three replicates.

Article Snippet: The dissociated cells were incubated with antibodies APC anti-CD82 (FAB4616A, R&D Systems, Minneapolis, MN, USA; RRID: AB_2076404), PE anti-ERBB3 (304706, BioLegend, San Diego, CA, USA; RRID: AB_2099569), and PECy7 anti-NGFR (Cat# 562122, BD Biosciences, San Jose, CA, USA; RRID: AB_10894762); each at 0.5 uL per 1 million cells) in FACS buffer for one hour on ice.

Techniques: Muscles, Injection, Isolation, Expressing, RNA Sequencing, Cell Culture, Staining, Transplantation Assay, Derivative Assay

Journal: Neurology® Neuroimmunology & Neuroinflammation

Article Title: αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell–related features

doi: 10.1212/NXI.0000000000000107

Figure Lengend Snippet: (A) Cluster of expanded Vβ1 + T cells within multiple sclerosis (MS) lesions. Immunohistochemistry for the expanded and persisting Vβ1 clone (green) in clusters of CD8 + T cells (red) in parenchymal MS lesions. Several such clusters were observed. Only very few scattered CD8 − Vβ1 + T cells could be identified in the brain lesion. Nuclei are visualized with 4',6-diamidino-2-phenylindole (white). Scale bar 20 µm. (B) Sequences of paired T-cell receptor (TCR) α and β chains. Single sorted or laser microdissected Vβ1 + CD8 + T cells from peripheral blood or brain sections were submitted to single-cell TCR PCR to identify Vβ1 chains and all possible matching α chains. The V, n(D)n, and J regions are indicated. Amino acids encoded by n(D)n nucleotides are printed in red. The expanded Vβ1-Jβ2.3 β chain (upper line) was found to pair with 4 different α chains. Three α chains were identified from brain lesions, and 1 α chain was found in blood. The α chains expressing the Jα33 (second line) and Jα16 (fifth line) elements were identified in 7 and 6 independent cells, respectively. All α chains share the Vα7.2 element, and even though they do not share the same Jα element, they all show homologous complementarity determining region 3α regions with a conserved valine (V) followed by a positively charged arginine (R) (with only one clone showing a glutamine [Q]), a negatively charged amino acid (D/E), and a relatively large hydrophilic amino acid. One of the α chains (highlighted in red) is the mucosal-associated invariant T (MAIT) cell canonical TCR Vα7.2-CAXXDSNYQLIW-Jα33 chain with 2 N nucleotide–encoded amino acids between Vα7.2 and Jα33 (here VR). The other clones with Jα16, Jα24.1, and Jα58 chains are atypical for MAIT cells, which usually carry Jα33, Jα20, or Jα12. PBMC = peripheral blood mononuclear cell.

Article Snippet: To characterize T-cell infiltrates in sections of MS brain, the following antibodies against cell surface molecules were used: mouse anti-human CD161 (1:5, 191B8, Miltenyi Biotec, Bergisch Gladbach, Germany), mouse anti-human Vα7.2 (1:5, 3C10, BioLegend, San Diego, CA), mouse anti-human CD8α (1:50, LT8, AbD Serotec, Kidlington, UK; labeled with the Cy3 MAb labeling kit, GE Healthcare, Freiburg, Germany), rabbit anti-human CCR7 (1:800, Y59, Abcam, Cambridge, UK), mouse anti-human CD45RA (1:250, HI100, BioLegend), mouse anti-human CD45RO (1:250, UCHL1, BioLegend), fluorescein isothiocyanate (FITC)-labeled mouse anti-human Vβ1 (1:100, BL37.2, Beckman Coulter, Brea, CA), rabbit anti-human CD3 (1:500, Dako, Glostrup, Denmark), and Alexa Fluor 488–conjugated mouse anti-human CD4 (1:50, RPA-T4, eBioscience, San Diego, CA).

Techniques: Immunohistochemistry, Expressing, Clone Assay

Journal: Neurology® Neuroimmunology & Neuroinflammation

Article Title: αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell–related features

doi: 10.1212/NXI.0000000000000107

Figure Lengend Snippet: Immunofluorescence staining of brain-infiltrating immune cells. All nuclei are stained with 4′,6-diamidino-2-phenylindole (white). Green and red dyes were used. Double-positive cells are therefore shown in yellow. Scale bars 50 µm. (A) Double staining for CD3 (green) and CD8α (red). Most CD3 + T cells coexpress CD8α. (B) CD8 + (red) T cells outnumber CD4 + (green) T cells. (C) Low numbers of CD45RA + (green) CD8 + (red) double-positive T cells in multiple sclerosis (MS) brain tissue. (D) Many CD8 + T cells (red) coexpress CD45RO (green). (E) Naive T cells double-positive for CCR7 (red) and CD45RA (green) are mostly found within blood vessels and are barely detectable in the parenchyma of MS CNS. (F) Effector memory (CD45RO + CCR7 − ) (green arrow) and central memory (CD45RO + CCR + ) (yellow arrow) T cells in MS lesions.

Article Snippet: To characterize T-cell infiltrates in sections of MS brain, the following antibodies against cell surface molecules were used: mouse anti-human CD161 (1:5, 191B8, Miltenyi Biotec, Bergisch Gladbach, Germany), mouse anti-human Vα7.2 (1:5, 3C10, BioLegend, San Diego, CA), mouse anti-human CD8α (1:50, LT8, AbD Serotec, Kidlington, UK; labeled with the Cy3 MAb labeling kit, GE Healthcare, Freiburg, Germany), rabbit anti-human CCR7 (1:800, Y59, Abcam, Cambridge, UK), mouse anti-human CD45RA (1:250, HI100, BioLegend), mouse anti-human CD45RO (1:250, UCHL1, BioLegend), fluorescein isothiocyanate (FITC)-labeled mouse anti-human Vβ1 (1:100, BL37.2, Beckman Coulter, Brea, CA), rabbit anti-human CD3 (1:500, Dako, Glostrup, Denmark), and Alexa Fluor 488–conjugated mouse anti-human CD4 (1:50, RPA-T4, eBioscience, San Diego, CA).

Techniques: Immunofluorescence, Staining, Double Staining

Journal: Neurology® Neuroimmunology & Neuroinflammation

Article Title: αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell–related features

doi: 10.1212/NXI.0000000000000107

Figure Lengend Snippet: Double fluorescence immunohistochemistry identifies brain-infiltrating mucosal-associated invariant T (MAIT) cells in multiple sclerosis (MS) lesions of patient A. Nuclei are stained with 4',6-diamidino-2-phenylindole (white). Green and red dyes were used. Double-positive cells are therefore shown in yellow. Scale bars 20 µm. (A) T cells expressing the T-cell receptor Vα7.2 (red) and Vβ1 chains (green). This combination (see ) was identified by single-cell PCR. (B) Most Vα7.2 + (green) T cells belong to the CD8 + (red) T-cell subset. (C) MAIT cells expressing Vα7.2 (red) and CD161 (green) in the parenchyma of MS brain. (D) The vast majority of CD161 + (green) cells in MS CNS coexpress CD8α (red).

Article Snippet: To characterize T-cell infiltrates in sections of MS brain, the following antibodies against cell surface molecules were used: mouse anti-human CD161 (1:5, 191B8, Miltenyi Biotec, Bergisch Gladbach, Germany), mouse anti-human Vα7.2 (1:5, 3C10, BioLegend, San Diego, CA), mouse anti-human CD8α (1:50, LT8, AbD Serotec, Kidlington, UK; labeled with the Cy3 MAb labeling kit, GE Healthcare, Freiburg, Germany), rabbit anti-human CCR7 (1:800, Y59, Abcam, Cambridge, UK), mouse anti-human CD45RA (1:250, HI100, BioLegend), mouse anti-human CD45RO (1:250, UCHL1, BioLegend), fluorescein isothiocyanate (FITC)-labeled mouse anti-human Vβ1 (1:100, BL37.2, Beckman Coulter, Brea, CA), rabbit anti-human CD3 (1:500, Dako, Glostrup, Denmark), and Alexa Fluor 488–conjugated mouse anti-human CD4 (1:50, RPA-T4, eBioscience, San Diego, CA).

Techniques: Fluorescence, Immunohistochemistry, Staining, Expressing

Journal: Neurology® Neuroimmunology & Neuroinflammation

Article Title: αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell–related features

doi: 10.1212/NXI.0000000000000107

Figure Lengend Snippet: Analysis of the T-cell receptor (TCR) Vα7.2 repertoire of patient A by pyrosequencing shows oligoclonal T-cell expansions in different samples. Each pie chart represents the total number of nucleotide sequences found in the Vα7.2 repertoire of a certain compartment and each sector represents one distinct T-cell clone. We compared (A) samples from CNS tissue from the biopsy taken in 1996, (B) Vα7.2 + CD161 + mucosal-associated invariant T (MAIT) cells, (C) Vα7.2 + CD161 − cells, (D) CD8 + cells, and (E) CD4 + T cells from peripheral blood taken in 2013 and 2014. For each population we list the designation of the Jα elements and their relative percentage. Clones carrying the MAIT canonical TCR α chain (CAXXDSNYQLIW) are marked in bright blue, and clones containing the noncanonical α chains characterized by Jα12 (CAXXDSSYKLIF) and Jα20 (CAVXXDYKLSF) are marked in dark blue and light blue, respectively. (F) Percentages of identical complementarity determining region 3α amino acid sequences within the TCR Vα7.2 + repertoire between the different samples defined above (A–E). The numbers are percentages indicating how often a particular sequence detected in one sample was also found in another sample. The greatest overlap was between Vα7.2 + CD161 + and CD8 + T cells from peripheral blood, but there was also significant overlap between the CNS sample and the Vα7.2 + CD161 + sample from 2013 to 2014, as highlighted by the red and yellow colors. PBMC = peripheral blood mononuclear cell.

Article Snippet: To characterize T-cell infiltrates in sections of MS brain, the following antibodies against cell surface molecules were used: mouse anti-human CD161 (1:5, 191B8, Miltenyi Biotec, Bergisch Gladbach, Germany), mouse anti-human Vα7.2 (1:5, 3C10, BioLegend, San Diego, CA), mouse anti-human CD8α (1:50, LT8, AbD Serotec, Kidlington, UK; labeled with the Cy3 MAb labeling kit, GE Healthcare, Freiburg, Germany), rabbit anti-human CCR7 (1:800, Y59, Abcam, Cambridge, UK), mouse anti-human CD45RA (1:250, HI100, BioLegend), mouse anti-human CD45RO (1:250, UCHL1, BioLegend), fluorescein isothiocyanate (FITC)-labeled mouse anti-human Vβ1 (1:100, BL37.2, Beckman Coulter, Brea, CA), rabbit anti-human CD3 (1:500, Dako, Glostrup, Denmark), and Alexa Fluor 488–conjugated mouse anti-human CD4 (1:50, RPA-T4, eBioscience, San Diego, CA).

Techniques: Clone Assay, Sequencing

Journal: bioRxiv

Article Title: Melanoblast transcriptome analysis reveals novel pathways promoting melanoma metastasis

doi: 10.1101/721712

Figure Lengend Snippet: a , Screen of known melanoma metastasis suppressor expression following KDELR3 knockdown (3 days post knockdown). P, Parental; C, siControl; K3, si KDELR3. b , qPCR of KAI1 RNA expression ( CD82 gene) in siRNA knockdown cells (indicated), 3 days post knockdown. c-e , KAI1 protein ( c ) and RNA ( d - e ) expression in 1205Lu cells transfected with CD82/KAI1 overexpression (KAI1) or PCMV6-AC control vector (Vec.), KDELR3 transcript 1with DDK tag (K3_1), KDELR3 transcript 2 with DDK tag (K3_2), or PCMV6 control vector (Vec.1). Harvested 3 days post transfection. Equal protein amounts subjected to immunoblot analysis with an anti-KAI1 and anti-DDK antibody and anti-VINCULIN loading control ( c ). f , 1205Lu cells parental (P), and 1205Lu cells transiently transfected with control siRNA (C), and KDELR3 siRNA (K3), harvested 3 days post transfection and equal protein amounts subjected to immunoblot analysis with an anti-KAI1 and anti-gp78 antibody. g , KAI1 protein expression in siRNA knockdown (indicated) 1205Lu cells harvested 3 days post transfection and treated with de-glycosylation enzymes (De-G). h , qPCR of gp78 RNA expression ( AMFR gene) in siRNA knockdown cells (indicated), 3 days post knockdown. f , g , Anti-vinculin antibody used to control for protein loading. i , qPCR of KDELR3 RNA expression in siRNA knockdown cells (indicated), 4 days post knockdown j , Co-immunoprecipitation of endogenous gp78 and mCherry tagged gp78 (gp78-mCh) with FLAG-tagged KDELR3 (K3-DDK) in stably transduced 1205Lu cells. Red line, gp78 expression. k , pol2 > KDELR3 -GFP (green) co-localizes with pol2> gp78 -mCherry (red) in 1205Lu metastatic melanoma cells. Scale bars, 50 µm. l , Schematic of the KDELR3-KAI1 axis in melanoma metastasis. a - f , h , j - k , Representative of three independent experiments. g , i , Representative of two independent experiments.

Article Snippet: For immunoblotting, the rabbit monoclonal antibody to CD82 (D7G6H) was used (Cell Signaling Technology Cat#12439S).

Techniques: Expressing, Knockdown, RNA Expression, Transfection, Over Expression, Control, Plasmid Preparation, Western Blot, Glycoproteomics, Immunoprecipitation, Stable Transfection

Journal: Asian Pacific Journal of Cancer Prevention : APJCP

Article Title: Down Regulation of KAI1/CD82 in Lymph Node Positive and Advanced T-Stage Group in Breast Cancer Patients

doi: 10.31557/APJCP.2019.20.11.3321

Figure Lengend Snippet: The Relationship Between mRNA Expression of KAI1-1 and Clinicopathological Factors from Breast Cancer Patients (n=100)

Article Snippet: The sections were incubated with the rabbit polyclonal anti KAI1 protein antibody (Proteintech, 10248-1-AP, USA) in a dilution of 1:200 at 4°C for overnight.

Techniques: Expressing

Journal: Asian Pacific Journal of Cancer Prevention : APJCP

Article Title: Down Regulation of KAI1/CD82 in Lymph Node Positive and Advanced T-Stage Group in Breast Cancer Patients

doi: 10.31557/APJCP.2019.20.11.3321

Figure Lengend Snippet: mRNA Expression Levels of KAI1in Cases and Controls and in Sub Groups of Cases. Benign breast disease group, Lymph node negative group and T1/T2 stage were taken as control and the fold change was considered as 1. mRNA expression of KAI1 is down regulated in breast carcinoma as compared to controls of benign breast disease. Further, KAI-1 expression is significantly down regulated in T3/T4 stage and node positive group of breast carcinoma with respect to T1/T2 stage and node negative groups of breast carcinoma respectively

Article Snippet: The sections were incubated with the rabbit polyclonal anti KAI1 protein antibody (Proteintech, 10248-1-AP, USA) in a dilution of 1:200 at 4°C for overnight.

Techniques: Expressing, Control

Journal: Asian Pacific Journal of Cancer Prevention : APJCP

Article Title: Down Regulation of KAI1/CD82 in Lymph Node Positive and Advanced T-Stage Group in Breast Cancer Patients

doi: 10.31557/APJCP.2019.20.11.3321

Figure Lengend Snippet: Western Blot Analysis of Protein Expression of KAI1and β Actin. Protein expression of KAI1 is lower in T3/T4 stage and node positive group (Lane2 & lane 4) compared to T1/T2 stage and node negative groups respectively

Article Snippet: The sections were incubated with the rabbit polyclonal anti KAI1 protein antibody (Proteintech, 10248-1-AP, USA) in a dilution of 1:200 at 4°C for overnight.

Techniques: Western Blot, Expressing

Journal: Asian Pacific Journal of Cancer Prevention : APJCP

Article Title: Down Regulation of KAI1/CD82 in Lymph Node Positive and Advanced T-Stage Group in Breast Cancer Patients

doi: 10.31557/APJCP.2019.20.11.3321

Figure Lengend Snippet: The Relationship Between Protein Expression of KAI-1 Investigated by IHC and Clinicopathological Factors from Breast Cancer Patients (n=60)

Article Snippet: The sections were incubated with the rabbit polyclonal anti KAI1 protein antibody (Proteintech, 10248-1-AP, USA) in a dilution of 1:200 at 4°C for overnight.

Techniques: Expressing

Journal: Asian Pacific Journal of Cancer Prevention : APJCP

Article Title: Down Regulation of KAI1/CD82 in Lymph Node Positive and Advanced T-Stage Group in Breast Cancer Patients

doi: 10.31557/APJCP.2019.20.11.3321

Figure Lengend Snippet: Representative Immunohistochemistry Staining for KAI1/CD82 Protein Expression in Paraffin-Embedded Breast Carcinoma. Fig 3a, strongly positive immunostaining i.e abundant expression of KAI1; Fig 3b, reduced immunostaining; Fig 3c, negative immunostaining

Article Snippet: The sections were incubated with the rabbit polyclonal anti KAI1 protein antibody (Proteintech, 10248-1-AP, USA) in a dilution of 1:200 at 4°C for overnight.

Techniques: Immunohistochemistry, Staining, Expressing, Immunostaining